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1. Introduction  
MicroRNAs (miRNAs or miRs) are a class of small noncoding RNAs of 19~22 nucleotides, 
and repress protein expression at the posttranscriptional level through imperfect or perfect 
base pairing with 3`untranslated region of the target mRNA in mammalian cells, leading to 
its reduced translation or mRNA degradation. Although miRs are thought to be involved in 
various biological processes, including development, differentiation, cell proliferation, cell 
death, and so on, accumulating evidence suggests that alterations of their expression may 
play a role in the development of human cancers(1-4). Specific miRNAs have been 
demonstrated to be deregulated in diverse cancer subtypes including lymphoma, colorectal 
cancer, lung cancer, breast cancer, papillary thyroid carcinoma, hepatocellular carcinoma, 
and glioblastoma(5-13). Ciafre et al. used microarray method to compare the global 
expression levels of 245 miRNAs in glioblastoma tissue with normal brain tissue and found 
that the expression of miR-221 was strongly upregulated in glioblastoma cells. They 
identified nine overexpression miRNAs including miR-221 and miR-222(miR-221/222) 
cluster (13). This chapter review how miR-221/222 cluster regulated glioma cell phenotype 
and it`s mechanism. 
2. miR-221 and miR-222 cluster regulated glioma cell phenotype and it`s 
mechanism 
In Ciafre study, they found that miR-221 and miR-222 overexpress in glioma tumor tissue 
and glioma cell line compare to normal brain tissue, as well as our microarray results. So, 
we question what biogenesis of miR-221 and miR-222 and this cluster miRs function. 
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2.1 Biogenesis of miR-221 and miR-222 and this tow miRs location 
MiR-221, miR-222 genes are clustered chromosome Xp11.3 in tandem. When zhanglilei 
research retinitis pigmentosa, they discover miR-221 and miR-222 genes. Two miR genes are 
located near the telomeric end of deletion ~700bp apart(mir-221：45,361,839-45,361,948 and 
mir-222：45,362,675-45,362,784) (14). Like some other clustered miRNA genes, two miRNA 
genes is high similariry in sequence and they might be transcribed as polycistrons (Fig 1). 
 
 
Fig. 1. A schematic representation defines the miR-221 and miR-222 sequences (arrow 
indicates identical seed sequences AGCUACAU as shown in GeneDoc, 
www.psc.edu/biomed /genedoc). 
As well as the other miRs, biogenesis of miR-221 and miR-222 are a multi-step process 
beginning with transcription by RNA polymerase ˨ of a primary transcript, called pri-
miRNA. This precursor is cleaved to form a 70nt long stem-loop precursor RNA(pre- 
miRNA) by an RNAse ˩ type endonuclease called Drosha inside the nucleus. RanGTP 
exportin 5 transports pre- miRNA to the cytoplasm, where another RNAse ˩, Dicer, cleaves 
the stem-loop structure to produce 19~23 nucleotide miRNA duplexes. That one of the two 
RNA strands is then included into the RNA-induced silencing complex(RISC) form 
asymmetric RISC assembley. Asymmetric RISC assembley is also called miRNP. It inhibit 
translation or mRNA degradation by miRNA complete pairing or incomplete pairing with 
mRNA 3`UTRs.(15-17) 
2.2 miR-221 and miR-222 cluster regulated glioma cell phenotype in vitro 
We already proved that miR-221 and miR-222 upregulted in glioma compared to normal 
brain tissue, and knowed this two miRs biogenesis and location in chromosome. 
Furthermore, we ready to research how the cluster miRs affect glioma cell phenotype, 
including proliferation, cell cycle, apoptosis, invasion and radiosensitivity, in vitro. 
Our previous work identified that a functional overlap between miR-221/222 in modulating 
glioma cell phenotype. So, we knocked down or ectopic express miR-221/222 to study their 
function. Firstly, by northern blot, it is identified that pMSCV-miR-221/222 increased miR-221 
and miR-222 level and anti-miR-221/222(AS-miR-221/222 or As-miR-221/222) knocked down 
miR-221 and miR-222 level (not show).By MTT assay, the glioma U251 cell proliferation rate in 
different transfected cells was measured. It was shown that the cells transfected with anti-miR-
221/222 were proliferated at a significantly lower rate than the other three groups (Figure 2). 
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Moreover, the cells transfected with pMSCV-miR-221/222 proliferated at a significantly higher 
rate than the control and the scramble groups (Figure 2). These data demonstrated that the 
growth rate of glioma cell could be co-modulated by miR-221 and miR-222. The result were 
also proved in the other tumors. Agami R et al found that miR-221 and miR-222 promote 
cancer cell proliferation(18). Frenquelli M et al also identified that miR-221 and miR-222 
promote cancer cell proliferation in chronic lymphocytic leukemia(19). The same result were 
also proved in human prostate carcinoma cell lines, human thyroid papillary carcinomas, 
human colorectal carcinoma, and so on(20-22).  
 
1 2 3 4 5 6
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
1.4
R
el
at
iv
e 
pr
ol
ife
ra
tiv
e 
ra
te
Days  after transfection
 anti-miR-221/222
 control
 scramble
 pMSCV-miR-221/222
 
Fig. 2. As-miR-221/222 decrease cell proliferation. MTT assay show that the cells transfected 
with As-miR-221/222 were proliferated at a significantly lower rate than the other four 
groups. The latitudinal axis represented days after cell implantation in the 96-well plate. The 
cell proliferation rate in parental U251 glioma cells was presented as 100%.  
The cell cycle distribution and cell apoptosis were analyzed by flow cytometry. The cell 
cycle distribution showed that the G0/G1 phase percentage of control, scramble treated cells 
was 28.6%, 26.0%, respectively; while the fraction of anti-miR-221/222 treated cells was 
46.2% and the fraction of pMSCV-miR-221/222 treated cells was 22.3%. The S phase fraction 
in control, scramble treated cells, anti-miR-221/222 treated cells, pMSCV-miR-221/222 
treated cells was 56.8%, 57.2%, 26.8%, 60%, respectively. No statistical significance of G2/M 
phase percentage was detected among the four groups (Fig. 3). Frenquelli M et al also 
identified that miR-221/222 promote cancer cell into S phase in chronic lymphocytic 
leukemia. They synchronized cells in the G1 phase and analyzed by flow cytometry the cell-
cycle distribution at 4, 6, and 24 hours after cell-cycle block release. The result document that 
miR-221– and miR-222–transduced cells progressed more quickly through the cell-cycle 
phases (19). The same result was also proved in human prostate carcinoma cell lines, human 
thyroid papillary carcinomas, human colorectal carcinoma, and so on (20-22). 
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Fig. 3. Co-suppression of miR-221/222 expression by as-miR-221/222 induce G1 arrest in 
U251 cell. Transfected and control cells were harvested by trypsinization, washed and fixed 
overnight. Nuclei of cells were stained with propidium iodide, a total of 10,000 nuclei were 
examined. By flow cytometry analysis, the rate of cell in G1 in anti-miR-221/222 group was 
higher significantly than the other four groups. 
Moreover, miR-221 and miR-222 inhibit glioma cell apoptosis. To examine biological 
significance of miR-221 and miR-222 in glioma, glioma U251 cells were treated with anti-
miR-221 /222. Interestingly, annexin V-labeling revealed that knockdown of miR-221 and 
miR-222 significantly increased cell apoptosis compared to the cells treated with scramble 
oligonucleotide (Fig. 4). In addition, caspase 3/7 activity was also considerably elevated in 
miR-221 and miR-222 knocked down cells (Fig. 5). Since collapse of the mitochondrial 
membrane potential is one of the early events in apoptosis (23), we next examined whether 
miR-221 and miR-222 regulate mitochondrial membrane potential. The cells with depletion 
of miR-221 and miR-222 were stained with cationic dye JC-1. FACSCalibur analysis showed 
that the mitochondrial membrane potential was largely damaged when miR-221 and miR-
222 were depleted (Fig. 6). These findings indicate that miR-221 and miR-222 play an 
important role in initiation of cell apoptosis(24). 
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Fig. 4. Annexin V analysis showed that U251 cells transfected with As-miR-221/222 
displayed significantly more apoptosis than the other three groups. 
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Fig. 5. Caspase 3/7 activity was considerably elevated in miR-221 and miR-222 knocked 
down cells compared to the other three group. 
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Fig. 6. U251 cells transfected with As-miR-221/222 showed a significantly greater collapse in 
mitochondrial membrane potential compared with the other four groups. 
Furthermore, Garofalo M et al proved that miR-221/222 modulated TIMP3 expression by 
binding it`s 3`UTR (25). Whether miR-221/222 modulated TIMP3 expression to affect 
glioma cell invasion or not. To further explore the role of miR-221/222 in cell invasion, we 
performed gain-of-function and loss-of-function analyses by over-expressing or suppressing 
miR-221/222 with anti-miR-221/222 or pMSCV-miR-221/222, respectively. Interestingly, 
the transwell assay revealed that knockdown of miR-221/222 significantly decreased cell 
invasion potential compared with cells treated with scrambled oligonucleotide, whereas 
over-expression of miR-221/222 increased cell invasion (Fig. 7). Consistent with the results 
of the transwell assay, in the wound healing assay, repression of miR-221/222 significantly 
inhibited cell migration, while over-expression of miR-221/222 increased migration in U251 
cells (Fig. 8). Therefore, miR-221 and miR-222 are required for glioma cell invasion. 
In addition to modulating proliferation, cell cycle, apoptosis and invasion, whether miR-221 
and miR-222 regulated glioma cell radiosensitivity or not. To test this hypothesis, we 
transfected AS-miR-221/-222 into U251 cells, then preformed the colony formation assay to 
elevated radiosensitivity. Figure 9 shows the survival curves for U251 cells transfected with 
control, anti-miR-221/-222, and scrambled oligonucleotides and then exposed to IR over a 
dose range of 0 to 6 Gy. We found that whereas scrambled oligonucleotides did not affect 
radiosensitivity, anti-miR-221/-222 transfection significantly decreased IR-induced survival. 
Radiation survival curves were characterized based on parameters such as the dose required 
to reduce survival to 37% of its value (D0), the surviving fraction at 2 Gy (SF2), and the 
sensitization enhancement ratio at 10% (SER10). The SER10 value for the U251 cells 
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transfected with AS-miR-221/-222 was 1.97 (Table 1) (p < 0.01 compared to the controls), 
indicating a radiosensitization potential for targeting miR-221/-222. Collectively, these 
observations provide strong evidence for the role of miR-221/-222 in regulation of 
radiosensitivity. 
 
 
Fig. 7. The transwell assay revealed that knockdown of miR-221/222 significantly decreased 
cell invasion potential compared with cells treated with scrambled oligonucleotide, whereas 
over-expression of miR-221/222 increased cell invasion 
 
 
Fig. 8. The wound healing assay, repression of miR-221/222 significantly inhibited cell 
migration, while over-expression of miR-221/222 increased migration in U251 cells 
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Fig. 9. miR-221/-222 knockdown leads to an increase of radiosensitivity. U251 cells stably 
transfected with control, AS-miR-221/-222, or scrambled ODN were exposed to 0 to 6 Gy IR 
and incubated for 2 weeks prior to fixation, staining, and assessment of colony formation. 
The clonogenic survival assays were performed in triplicate. Standard errors of the mean are 
shown by error bars. 
 
 
Abbreviations: D0 = dose to reduce survival to 37% of its value; SF2 = surviving fraction at 2 
Gy; SER10 = sensitizer enhancement ratio at 10% survival.* p<0.01. 
Table 1. Radiosensitizing effects of respective cell lines 
 
 
Fig. 10. SLDT assay showed that the functional GJIC in AS-miR-221/222 treated U251 cells 
were re-established, lucifer yellow was transferred to multiple rows of cells nearby the 
scrape border. 
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In addition, by Scrape loading and dye transfer (SLDT) assay, we found that miR-221 and 
miR-222 also regulated gap junction intercellular communication (GJIC) of glioma cell. 
2.3 miR-221 and miR-222 cluster promote glioma growth in vivo 
In vitro, miR-221/222 modulated glioma cell growth by regulating cell cycle, apoptosis, and 
invasion, and so on. Whether these results are right or not in vivo. Ciafre et al firstly proved 
that the anti-miR-221/222 antagomir treatment of established subcutaneous tumors derived 
from the highly aggressive PC3 cell line, naturally expressing high levels of miR-221/222, 
reduces tumor growth by increasing intratumoral p27 amount; this effect is long lasting, as 
it is detectable as long as 25 days after the treatment(26). We used 5-week-old female 
immune-deficient nude mice (BALB/C-nu) to perform related experiment. It were housed 
in microisolator individually ventilated cages with water and food. All experimental 
procedures were carried out according to the regulations and internal biosafety and 
bioethics guidelines of Tianjin Medical University and the Tianjin Municipal Science and 
Technology Commission. U251 glioma subcutaneous model was established as previously 
described (27). When the volumer of the subcutaneous tumor reached 50 mm3, the mice 
were randomly divided into four groups (ten mice/group). A mixture of 5 μl 
oligonucleotides containing Scr, AS-miR-221, AS-miR-222 or equal mount of AS-miR-
221/222 cluster and 10 μl Lipofectamine was injected into the xenograft tumor model using 
a multi-site injection manner. Mice in U251 control group received 10 μl of PBS only. 
Treatment was conducted one time every three days and five times in all (Please confirm if it 
is correct). The tumor volume was measured with a caliper every two days, using the 
formula volume = length × width2/2. 
Fluorescence in situ hybridization proved that As-miR-221 and As-miR-222 efficiently and 
specifically silenced endogenous miR-221 and miR-222, respectively, in xenograft tumor in 
vivo (Figure 11).Moveover, we have found that transfection of U251 cells with As-miR-
221/222 mediated significant inhibition of tumor growth in a xenograft tumor mouse model 
(Figure 12). Tumor pathological examination of xenograft tumors demonstrated that, in 
control and scramble group, more neonatal micro-vessels, bigger tumor cell nucleus, deeper 
blue staining chromosome, more mitotic tumor cells and lesser necrosis focuses were 
 
 
 
 
Fig. 11. Tumor pathological section of xenograft tumors show that miR-221 and miR-222 
expression were knocked down by As-miR-221/222 in vivo by fluorescence in situ 
hybridization . 
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observed than in As-miR-221/222 treatment group (Figure13). All these morphological 
changes among the three different treated groups indicate that the xenograft tumor without 
effective As-miR-221/222 therapy can perform relative more malignant pathological 
manifestation. TUNEL assay analysis of xenograft tumor taken at 28 days after treatment 
revealed much more apoptosis in As-miR221/222 group when compared to tumors from 
scramble and control groups (Figure14). Also, the As-miR-221/222 treated tumors had a 
lower level of Ki-67 expression compared to the other four groups group. Tumor 
immunochemistry examination of xenograft tumors demonstrated that some protein 
expression level in As-miR-221/222 group was up-regulated significantly than the other 
four groups, such as p27, puma, PTEN, TIMP3, and so on. Some protein expression levels in 
As-miR-221/222 group was down-regulated significantly than the other four groups, such 
as CyclinD, MMP2, MMP9, pAkt, and so on (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. Transfection of U251 cells with As-miR-221/222 mediated significant inhibition of 
tumor growth in a xenograft tumor mouse model. 
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Fig. 13. Tumor pathological examination of xenograft tumors demonstrated that, in control 
and scramble group, more neonatal micro-vessels, bigger tumor cell nucleus, deeper blue 
staining chromosome, more mitotic tumor cells and lesser necrosis focuses were observed 
than in As-miR-221/222 treatment group. 
 
 
 
 
 
 
 
 
 
 
Fig. 14. TUNEL assay revealed much more apoptosis in As-miR221/222 group when 
compared to tumors from scramble and control groups. 
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Fig. 15. Tumor immunochemistry examination of xenograft tumors demonstrated that some 
protein expression level in As-miR-221/222 group was up-regulated significantly than the 
other four groups and the other proteins expression level in As-miR-221/222 group was 
down-regulated. 
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2.4 The mechanism on miR-221 and miR-222 cluster modulate glioma cell malignant 
phenotype  
MiRs repress protein expression at the posttranscriptional level through imperfect base 
pairing with 3`untranslated region of the target mRNA in mammalian cells, leading to its 
reduced translation in order to affect cell function. That is, function of miRs depend on 
function of it target. So, it is necessary to identify targets of miRs. Bioinformatic analysis is 
the most effective approach to study miRNAs. We search some target by miRs target 
database, such as PicTar, TargetScan, and so on. Then, by luciferase assay, these targets were 
identified. As for miR-221 and miR-222, we proved that p27, PUMA, PTEN, TIMP3 and 
Cx43 were some targets of miR-221 and miR-222 in glioma. 
2.4.1 p27Kip1 
The p27Kip1 gene is a member of the cip/kip family of cyclin-dependent kinase (CDK) 
inhibitors that negatively control the cell cycle progression. The p27Kip1 binds to CDK2 and 
cyclin E complexes to prevent cell cycle progression from G1 to S phase (28,29). The p27Kip1 
does not follow Knudson's classic ‘two-hit hypothesis’ of tumor suppression. The 
inactivation of p27Kip1 is not caused by direct mutations in the gene encoding p27Kip1. The 
homozygous loss or silencing of the locus in human tumors is extremely rare (30). A recent 
study demonstrated that the miR-221/222 cluster is an endogenous regulator of p27Kip1, 
confirming the miRNA modulation may play a key role in the inactivation of p27Kip1 (31-34). 
However, that the miR-221/222 cluster affects tumor cell proliferation by regulating p27Kip1 
in vivo has not been well documented. 
2.4.2 PUMA 
Puma was originally identified during large-scale analysis for novel p53-inducible genes 
and Bcl-2-interacting proteins. Puma is an extremely potent BH3-only protein, having the 
capacity to bind with high affinity to all known anti-apoptotic Bcl-2 proteins. In addition, 
Puma may also directly interact with and activate Bax/Bak, for example, through an 
interaction with the first α-helix of Bax. In keeping with its highly pro-apoptotic nature, 
Puma has been shown to have an essential role in the induction of apoptosis in numerous in 
vitro and in vivo systems and cell types including neurons, lymphocytes, thymocytes, 
fibroblasts and cardiomyocytes. Puma expression is regulated by transcription, and factors 
regulating Puma ranscription include p53, p73, E2F and FOXO3a (24,35). 
2.4.3 PTEN 
The PTEN (phosphatase and tensin homology) gene, located at 10q23.3, encodes a central 
domain with homology to the catalytic region of protein tyrosine phosphatases. It is 
important in the function of protein phosphatases and 3’ -phosphoinositol phosphatase 
acivities. It dephosphorylates phosphatidylinositol-3,4,5-triphosphate(PIP3), the second 
messenger produced by PI3K. In do so, PTEN negatively regulates the activity of the 
serine/threonine protein kinase, AKt(36-37). PTEN is inactivated  in some malignant 
tumors, including glioblastoma 、prostate cancer、melanoma、endometrial carcinoma and 
lung carcinoma. To restore PTEN expression become an approach which enhances cancer 
radiosensitivity instead of suppressing Akt activity in PTEN-deficient tumor cells(38). 
2.4.4 TIMP3 
Malignant glioma cells express certain known proteinases such as matrix metalloproteinases 
(MMPs), which have been implicated as important factors in regulating cell invasiveness in 
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gliomas(39). MMPs are a family of at least 20 zinc-dependent endopeptidases collectively 
capable of degrading essentially all extracellular matrix(ECM) components, including 
collagents, fibronectin, laminin and basement membrance proteoglycans (40). Among the 
MMPs, attention has focused on gelatinases(MMP-2 and MMP-9) in human gliomas. A high 
level of MMP-2 expression was observed in the higher-grade gliomas, which correlated well 
with the malignant potential of human gliomas (41). A major mechanism for controlling 
MMPs activity in the pericellular space is mediated by the action of tissue inhibitors of 
metalloproteinases (TIMPs), which bind to active MMPs in a 1:1 molar stoichiometry (42). 
There are four family member, including TIMP-1, TIMP-2, TIMP-3, TIMP-4 (43). TIMP-3 is 
unique within the TIMP family as it remains closely associated to the extracellular matrix 
after being secreted by the cell (40, 44). In human gliomas, TIMP expression is reported to be 
down-regulated with increasing malignancy, including TIMP-3 (44). 
2.4.5 Cx43 
Cx genes have been demonstrated as tumor suppressor genes. Up to date, twenty members of 
Cx genes have been identified in mammalian tissues and they are expressed in tissue specific 
manner. Cx43 is the predominant form of Cxs expressed in astrocytes and also the constituent 
of connexons which compose the gap junction intercellular communication(GJIC) in brain (45, 
46). Our previous study and other studies showed that Cx 43 expression was inversely 
correlated with the degree of malignancy of astrocytomas (47). In most malignant gliomas, 
Cx43 expression was reduced or deleted and GJIC was deficient (47). 
In addition these target above, c-kit, p57, ERα,Bmf are also is some target of miR-221 and 
miR-222, but they are not proved in glioma until now (48-51). 
2.5 Inter-relationship between miR-221 and miR-222 expression and global mRNA 
expression 
Studies above have identified some targets of miR-221 and miR-222, such as p27, p57, and so 
on. Inter-relationship between miR-221 and miR-222 expression and global mRNA 
expression remains important as well. Here we knocked down miR-221 and miR-222 
expression and found 158 differentially expressed genes with 2-fold changes in U251 glioma 
cells by microarray analysis. Using the KEGG pathway databases and BioCarta, we found 
that the IFN-α signaling pathway was the most significant pathway modulated by 
differentially expressed genes. STAT1 and STAT2 are core proteins in the IFN-α signaling 
pathway. By Western blotting and immunofluorescence, we found that STAT1 and STAT2 
expression and phosphorylation were upregulated in U251 cells with knocked-down miR-
221/222. Furthermore, tyrosine phosphorylation of STAT1 and STAT2 was present in the 
nucleus after repression of miR-221/222 expression in U251 cells. These data indicate for the 
first time a mechanism involving STAT1/2 upregulation under the transcriptional control of 
INF-αsignaling after knockdown of miR-221/222 cluster in U251 glioma cells. 
2.6 Transcription factor modulate miR-221 and miR-222 expression  
MiRNAs finely modulate virtually all physiological pathways in metazoans, and are deeply 
implicated in all main pathologies by regulating their taregets. But who regulate them 
expression. Ciafrè et al report that the ectopic modulation of NF-kB modifies miR-221/222 
expression in prostate carcinoma and glioblastoma cell lines, where we had previously 
shown their oncogenic activity. We identify two separate distal regions upstream of miR-
221/222 promoter which are bound by the NF-kB subunit p65 and drive efficient 
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transcription in luciferase reporter assays; consistently, the site-directed mutagenesis 
disrupting p65 binding sites or the ectopical inhibition of NF-kB activity significantly reduce 
luciferase activity. In the most distal enhancer region, we also define a binding site for c-Jun, 
and we show that the binding of this factor cooperates with that of p65, fully accounting for 
the observed upregulation of miR-221/222. Thus, our work uncovers an additional 
mechanism through which NF-kB and c-Jun, two transcription factors deeply involved in 
cancer onset and progression, contribute to oncogenesis, by inducing miR-221/222 
transcription (52).Moreover, Garofalo et al also identified that c-jun regulated miR-221 and 
miR-222 expression level. 
 
 
Fig. 16. Constructed network of miR-221/222-TFs-STAT1/2-gene expression. Genes 
involved in TF-gene expression in glioma U251 cells after repression of the miR-221/222 
cluster, determining the cell death or survival through the INF-α pathway. Genes 
associated with eight TFs (FOS, ESR1,ETS2, IRF2, ARNT, ETS1, HOXC1, FOXN2) were 
manually identified via literature mining. IRF-1, STAT1 and STAT2 regulate the balance 
between miR-221/222-TFs and TF-gene expression, determining the cell death or survival 
through the INF-α pathway in glioma U251 cells. The INF-α pathway regulates cell 
survival negatively, via processes occurring in multiple intracellular compartments. 
Regulatory relationships are denoted by line colors, including the 28 genes and 64 verified 
modulation nodes. 
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3. Conclusion 
In summary, We first identified that miR-221 and miR-222 play an role in malignant 
phenotype of glioma by increasing or knocking down miR-221 and miR-222. It was found 
that miR-221/222 increased cell proliferation, increased S phase proportionality, inhibited 
cell apoptosis, increased cell invasion and migration, enhanced radioresistance and reduced 
gap junction intercellular communication (GJIC) in glioma U251 cell. Furthermore, 
knockeddown miR-221/222 considerably decreases tumor growth in U251 cell xenograft 
model. Then, we identified that p27kip1, PUMA, PTEN, TIMP3 and Cx43 are some targets 
of miR-221 and miR-222. We also found that knocked down miR-221/222 changed some 
proteins expression. Taken together, our studies provide evidence that miR-221/222 
regulate its target genes and its related transduction signal way to promote the growth of 
malignant glioma cells. So, we thought that miR-221 and miR-222 may serve as a novel 
therapeutic target for malignant gliomas.  
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